Conference Coverage

Canagliflozin falls short for primary CV prevention in T2DM

Publish date: February 2, 2018

 

REPORTING FROM THE AHA SCIENTIFIC SESSIONS

SOURCE: Mahaffey KW et al. AHA Scientific Sessions.

Pages

Recommended Reading

Shedding light on shift work’s influence on cardiometabolic risk
MDedge Endocrinology
Bariatric surgery comes with some risk of complications
MDedge Endocrinology
Breastfeeding lowers later diabetes risk in women
MDedge Endocrinology
Insulin delivery devices now covered under Part D
MDedge Endocrinology
Gastric bypass T2D benefit can fade over time
MDedge Endocrinology
Listen up: Acoustic device useful for diabetic foot ulcers
MDedge Endocrinology
New hematologic, cardiovascular system link may have therapeutic implications
MDedge Endocrinology
How to prioritize CVD reduction in type 2 diabetes
MDedge Endocrinology
Learn ‘four Ds’ approach to heart failure in diabetes
MDedge Endocrinology
Three in 10 of your diabetic patients may have liver fibrosis
MDedge Endocrinology